卡莱尔伙伴

近日，荷兰生物技术公司VarmX与全球血制品龙头企业CSL达成战略合作，以支持其主要资产VMX-C001的开发。
VarmX是一家生物技术公司，致力于开发创新方法，绕过针对活化因子Xa（FXa-DOACs）和遗传性凝血障碍的直接口服抗凝剂。
其主要资产VMX-C001是一种改良的重组人凝血因子Xa，可帮助需要紧...

$卡莱尔伙伴(CSL)$ 8-K Current report, items 5.02, 7.01, and 9.01 Accession Number: 0000790051-25-000161  Act: 34  Size: 466 KB 网页链接

$卡莱尔伙伴(CSL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001683884-25-000006  Size: 5 KB 网页链接

$卡莱尔伙伴(CSL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001800547-25-000005  Size: 5 KB 网页链接

$卡莱尔伙伴(CSL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001547351-25-000007  Size: 5 KB 网页链接

$卡莱尔伙伴(CSL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001594032-25-000008  Size: 8 KB 网页链接

$卡莱尔伙伴(CSL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000790051-25-000163  Size: 4 KB 网页链接

$卡莱尔伙伴(CSL)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000790051-25-000157  Act: 34  Size: 1 MB 网页链接

$卡莱尔伙伴(CSL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001477666-25-000007  Size: 5 KB 网页链接

$卡莱尔伙伴(CSL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001628280-25-054657  Size: 5 KB 网页链接

$卡莱尔伙伴(CSL)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000790051-25-000159  Act: 34  Size: 8 MB 网页链接

$卡莱尔伙伴(CSL)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001848829-25-000003  Size: 379 KB 网页链接

$卡莱尔伙伴(CSL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001628280-25-055264  Size: 5 KB 网页链接